Scolaris Content Display Scolaris Content Display

قطع یا اجتناب از مصرف استروئیدها در دریافت کنندگان پیوند کلیه

Appendices

Appendix 1. Electronic search strategies

Database

Search terms

CENTRAL

1. Kidney Transplantation [MESH]
2. kidney transplant*
3. 1 or 2
4. (avoid* or minim* or free* or withdraw* or spar* or discontinu* or taper* or conversion* or convert*) near25 (predniso* or corticosteroid* or steroid*)
5. 3 and 4

MEDLINE

1. Kidney Transplantation/
2. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or conversion$ or convert$) adj25 (predniso$ or corticosteroid$ or steroid$)).tw.
3. and/1‐2

EMBASE

1. exp kidney transplantation/
2. Drug Withdrawal/
3. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or conversion$ or convert$) adj25 (predniso$ or corticosteroid$ or steroid$)).tw.
4. or/2‐3
5. and/1,4

Appendix 2. Risk of bias assessment tool

Potential source of bias

Assessment criteria

Random sequence generation

Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence

Low risk of bias: Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).

High risk of bias: Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.

Unclear: Insufficient information about the sequence generation process to permit judgement.

Allocation concealment

Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment

Low risk of bias: Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web‐based, and pharmacy‐controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).

High risk of bias: Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non‐opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

Unclear: Randomisation stated but no information on method used is available.

Blinding of participants and personnel

Performance bias due to knowledge of the allocated interventions by participants and personnel during the study

Low risk of bias: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.

High risk of bias: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.

Unclear: Insufficient information to permit judgement

Blinding of outcome assessment

Detection bias due to knowledge of the allocated interventions by outcome assessors.

Low risk of bias: No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.

High risk of bias: No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

Unclear: Insufficient information to permit judgement

Incomplete outcome data

Attrition bias due to amount, nature or handling of incomplete outcome data.

Low risk of bias: No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.

High risk of bias: Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; ‘as‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.

Unclear: Insufficient information to permit judgement

Selective reporting

Reporting bias due to selective outcome reporting

Low risk of bias: The study protocol is available and all of the study’s pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon).

High risk of bias: Not all of the study’s pre‐specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified; one or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear: Insufficient information to permit judgement

Other bias

Bias due to problems not covered elsewhere in the table

Low risk of bias: The study appears to be free of other sources of bias.

High risk of bias: Had a potential source of bias related to the specific study design used; stopped early due to some data‐dependent process (including a formal‐stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.

Unclear: Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
Figuras y tablas -
Figure 3

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies

Funnel plot of comparisons that included at least 10 studies in the meta‐analysis
Figuras y tablas -
Figure 4

Funnel plot of comparisons that included at least 10 studies in the meta‐analysis

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 1 Death and graft loss.
Figuras y tablas -
Analysis 1.1

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 1 Death and graft loss.

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 2 Rejection.
Figuras y tablas -
Analysis 1.2

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 2 Rejection.

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 3 New‐onset diabetes after transplantation and cardiovascular events.
Figuras y tablas -
Analysis 1.3

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 3 New‐onset diabetes after transplantation and cardiovascular events.

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 4 Infection and malignancy.
Figuras y tablas -
Analysis 1.4

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 4 Infection and malignancy.

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 5 Kidney function.
Figuras y tablas -
Analysis 1.5

Comparison 1 Steroid withdrawal versus steroid maintenance, Outcome 5 Kidney function.

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 1 Death and graft loss.
Figuras y tablas -
Analysis 2.1

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 1 Death and graft loss.

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 2 Rejection.
Figuras y tablas -
Analysis 2.2

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 2 Rejection.

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 3 New‐onset diabetes after transplantation and cardiovascular events.
Figuras y tablas -
Analysis 2.3

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 3 New‐onset diabetes after transplantation and cardiovascular events.

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 4 Infection and malignancy.
Figuras y tablas -
Analysis 2.4

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 4 Infection and malignancy.

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 5 Kidney function.
Figuras y tablas -
Analysis 2.5

Comparison 2 Steroid avoidance versus steroid maintenance, Outcome 5 Kidney function.

Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 1 Death and graft loss.
Figuras y tablas -
Analysis 3.1

Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 1 Death and graft loss.

Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 2 Rejection.
Figuras y tablas -
Analysis 3.2

Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 2 Rejection.

Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 3 New‐onset diabetes after transplantation, infection, malignancy.
Figuras y tablas -
Analysis 3.3

Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 3 New‐onset diabetes after transplantation, infection, malignancy.

Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 4 Kidney function.
Figuras y tablas -
Analysis 3.4

Comparison 3 Steroid avoidance versus steroid withdrawal, Outcome 4 Kidney function.

Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 1 Death and graft loss.
Figuras y tablas -
Analysis 4.1

Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 1 Death and graft loss.

Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 2 Rejection, malignancy.
Figuras y tablas -
Analysis 4.2

Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 2 Rejection, malignancy.

Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 3 Kidney function.
Figuras y tablas -
Analysis 4.3

Comparison 4 Steroid withdrawal versus maintenance in children, Outcome 3 Kidney function.

Comparison 5 Publication bias, Outcome 1 Funnel plots.
Figuras y tablas -
Analysis 5.1

Comparison 5 Publication bias, Outcome 1 Funnel plots.

Summary of findings for the main comparison. Steroid withdrawal versus steroid maintenance for kidney transplant recipients

Steroid withdrawal versus steroid maintenance for kidney transplant recipients

Patient or population: kidney transplant recipients
Intervention: steroid withdrawal
Comparison: steroid maintenance

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Assumed risk

Corresponding risk

Steroid maintenance

Steroid withdrawal

Mortality
Follow‐up: 1 year

22 per 1000

15 per 1000
(8 to 29)

RR 0.68
(0.36 to 1.3)

1913 (10)

⊕⊕⊝⊝
low1,2

Graft loss (excluding death)
Follow‐up: 1 year

32 per 1000

38 per 1000
(23 to 62)

RR 1.17
(0.72 to 1.92)

1817 (8)

⊕⊕⊝⊝
low2,3

Acute rejection
Follow‐up: 1 year

152 per 1000

268 per 1000
(182 to 396)

RR 1.77
(1.2 to 2.61)

1913 (10)

⊕⊕⊕⊝
moderate1

NODAT
Follow‐up: 5 years

57 per 1000

44 per 1000
(28 to 69)

RR 0.77
(0.49 to 1.21)

1439 (6)

⊕⊕⊝⊝
low2,4

CMV infection
Follow‐up: 5 years

100 per 1000

104 per 1000
(80 to 137)

RR 1.04
(0.8 to 1.36)

1758 (5)

⊕⊕⊝⊝
low2,5

*The assumed risk is the baseline risk in the control group treated with steroid maintenance. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; NODAT: new‐onset diabetes after transplantation; CMV ‐ cytomegalovirus

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Most studies were unblinded (9 studies) and did not report details about random sequence generation or allocation concealment or both (8 studies). One study had inappropriate random sequence generation. Four studies were industry sponsored. ITT analysis was unclear in four.
2 Total number of events were fewer than 300.
3 Most studies were unblinded (7 studies) and did not report details about random sequence generation or allocation concealment or both (6 studies). One study had inappropriate random sequence generation. Four studies were industry sponsored. ITT analysis was unclear in two.
4 Most studies were unblinded (5 studies) and did not report details about random sequence generation or allocation concealment or both (5 studies). Three studies were industry sponsored. ITT analysis was unclear in three studies. One study had selective outcome reporting.
5 Most studies were unblinded (4 studies) and did not report details about random sequence generation or allocation concealment or both (4 studies). Three studies were industry sponsored. ITT analysis was unclear in two studies. One study had selective outcome reporting.

Figuras y tablas -
Summary of findings for the main comparison. Steroid withdrawal versus steroid maintenance for kidney transplant recipients
Summary of findings 2. Steroid avoidance versus steroid maintenance for kidney transplant recipients

Steroid avoidance versus steroid maintenance for kidney transplant recipients

Patient or population: kidney transplant recipients
Intervention: steroid avoidance
Comparison: steroid maintenance

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Control

Steroid avoidance versus steroid maintenance

Mortality
Follow‐up: 1 year

31 per 1000

30 per 1000
(16 to 56)

RR 0.96
(0.52 to 1.8)

1462 (10)

⊕⊕⊝⊝
low1,2

Graft loss (excluding death)
Follow‐up: 1 year

42 per 1000

46 per 1000
(27 to 79)

RR 1.09
(0.64 to 1.86)

1211 (7)

⊕⊕⊝⊝
low2,3

Acute rejection
Follow‐up: 1 year

204 per 1000

323 per 1000
(221 to 470)

RR 1.58
(1.08 to 2.3)

835 (7)

⊕⊕⊕⊝
moderate4

NODAT
Follow‐up: 5 years

107 per 1000

80 per 1000
(54 to 117)

RR 0.75
(0.51 to 1.1)

1618 (9)

⊕⊕⊝⊝
low2,5

CMV Infection
Follow‐up: 5 years

106 per 1000

101 per 1000
(74 to 138)

RR 0.96
(0.7 to 1.31)

1454 (6)

⊕⊕⊝⊝
low2,6

*The assumed risk is the baseline risk in the control group treated with steroid maintenance. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; NODAT: new‐onset diabetes after transplantation; CMV ‐ cytomegalovirus

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate

1 All studies were unblinded. Six studies were industry sponsored. In six studies random sequence generation or allocation concealment or both was unclear. In two studies ITT was either not performed or unclear. One study had selective outcome reporting
2 Total number of events was fewer than 300
3 All studies were unblinded. Five studies were industry sponsored. In four studies random sequence generation or allocation concealment or both was unclear. ITT was unclear in one study. One study had selective outcome reporting
4 All studies were unblinded. Five studies were industry sponsored. In four studies random sequence generation or allocation concealment or both was unclear. In three studies ITT was either not performed or unclear. One study had selective outcome reporting
5 Most studies were unblinded (8 studies). Five studies were industry sponsored. In four studies random sequence generation or allocation concealment or both was unclear. One study had selective outcome reporting
6 Most studies were unblinded (5 studies). Four studies were industry sponsored. One study had unclear ITT

Figuras y tablas -
Summary of findings 2. Steroid avoidance versus steroid maintenance for kidney transplant recipients
Table 1. Steroid withdrawal versus steroid maintenance ‐ stratified subgroup and sensitivity analysis for death, graft loss and acute rejection up to one year after transplantation

Death

Graft loss

Acute rejection

Biopsy‐proven acute rejection

Studies

RR

95% CI

Studies

RR

95% CI

Studies

RR

95% CI

Studies

RR

95% CI

Publication status

Peer reviewed journal

8

0.60

0.31 to 1.17

7

1.25

0.73 to 2.13

8

2.02

1.23 to 3.23

4

1.32

0.66 to 2.66

Abstract only

2

3.04

0.33 to 28.29

1

0.82

0.23 to 2.94

2

1.25

0.67 to 2.32

1

1.37

0.70 to 2.69

ITT analysis

ITT analysis used

6

0.69

0.30 to 1.61

6

1.31

0.69 to 2.46

6

2.07

1.10 to 3.91

3

1.37

0.64 to 2.94

ITT analysis not used/unclear

4

0.67

0.25 to 1.81

2

1.00

0.46 to 2.17

4

1.65

0.81 to 3.36

2

1.04

0.24 to 4.59

Calcineurin inhibitor

CsA

9

0.75

0.36 to 1.54

7

0.90

0.50 to 5.14

9

2.08

1.29 to 3.35

4

1.60

0.87 to 2.92

TAC

1

0.50

0.13 to 1.97

1

2.13

0.88 to 5.14

1

1.11

0.82 to 1.51

1

0.89

0.61 to 1.30

Antimetabolite

MMF or EC‐MPS

6

0.67

0.31 to 1.47

5

1.25

0.75 to 2.08

6

1.41

1.02 to 1.94

3

1.27

0.81 to 2.00

AZA

2

0.93

0.26 to 3.40

2

0.25

0.03 to 2.18

2

2.61

0.62 to 10.91

1

0.33

0.04 to 2.56

MMF or EC‐MPS or AZA

8

0.73

0.38 to 1.43

7

1.15

0.70 to 1.89

8

1.46

1.07 to 1.98

4

1.19

0.75 to 1.90

none

2

0.31

0.03 to 2.95

1

3.00

0.13 to 71.61

2

5.80

2.16 to 15.57

1

9.00

1.19 to 67.93

Induction treatment

Induction (yes)

2

3.00

0.32 to 27.87

1

0.33

0.01 to 8.02

2

0.80

0.22 to 2.91

NA

‐‐

‐‐

Induction (no)

8

0.60

0.31 to 1.17

7

1.21

0.74 to 1.99

8

1.93

1.26 to 2.94

NA

‐‐

‐‐

AZA ‐ azathioprine; CI ‐ confidence interval; CsA ‐ cyclosporin A; EC‐MPS ‐ enteric‐coated mycophenolate sodium; ITT ‐ intention to treat; MMF ‐ mycophenolate mofetil; NA ‐ not available; RR ‐ risk ratio; TAC ‐ tacrolimus

Figuras y tablas -
Table 1. Steroid withdrawal versus steroid maintenance ‐ stratified subgroup and sensitivity analysis for death, graft loss and acute rejection up to one year after transplantation
Table 2. Steroid avoidance versus steroid maintenance ‐ stratified subgroup and sensitivity analysis for death, graft loss and acute rejection up to one year after transplantation

Death

Graft loss

Acute rejection

Biopsy‐proven acute rejection

Studies

RR

95% CI

Studies

RR

95% CI

Studies

RR

95% CI

Studies

RR

95% CI

ITT analysis

ITT analysis used

7

1.16

0.48 to 2.83

5

1.09

0.56 to 2.11

4

1.92

1.18 to 3.14

4

2.31

1.47 to 3.63

ITT analysis not used/unclear

3

0.51

0.07 to 3.83

2

1.11

0.46 to 2.67

3

1.24

0.97 to 1.59

2

1.05

0.49 to 2.23

Calcineurin inhibitor

CsA

8

0.88

0.47 to 1.66

5

1.08

0.59 to 1.99

5

1.31

1.05 to 1.63

3

1.89

1.29 to 2.79

TAC

2

6.82

0.36 to 130.81

2

1.14

0.39 to 3.3

2

2.40

1.05 to 5.49

3

1.81

0.66 to 4.99

Antimetabolite

MMF or EC‐MPS

6

1.15

0.36 to 3.69

6

1.09

0.56 to 2.11

5

1.87

1.20 to 2.91

6

1.94

1.26 to 2.98

AZA

1

1.64

0.29 to 9.2

NA

‐‐

‐‐

NA

‐‐

‐‐

NA

‐‐

‐‐

MMF or EC‐MPS or AZA

8

1.16

0.48 to 2.83

NA

‐‐

‐‐

NA

‐‐

‐‐

NA

‐‐

‐‐

None

2

0.51

0.07 to 3.83

1

1.11

0.46 to 2.67

2

1.26

0.95 to 1.65

NA

‐‐

‐‐

Induction treatment

Induction (yes)

7

0.97

0.38 to 2.48

5

1.06

0.45 to 2.46

4

1.50

0.97 to 2.32

5

1.67

1.19 to 2.36

Induction (no)

3

0.92

0.17 to 5.01

2

1.12

0.57 to 2.2

3

1.72

0.89 to 3.32

1

3.89

2.16 to 7.03

AZA ‐ azathioprine; CI ‐ confidence interval; CsA ‐ cyclosporin A; EC‐MPS ‐ enteric‐coated mycophenolate sodium; ITT ‐ intention to treat; MMF ‐ mycophenolate mofetil; NA ‐ not available; RR ‐ risk ratio; TAC ‐ tacrolimus

Figuras y tablas -
Table 2. Steroid avoidance versus steroid maintenance ‐ stratified subgroup and sensitivity analysis for death, graft loss and acute rejection up to one year after transplantation
Comparison 1. Steroid withdrawal versus steroid maintenance

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death and graft loss Show forest plot

15

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Death up to one year

10

1913

Risk Ratio (M‐H, Random, 95% CI)

0.68 [0.36, 1.30]

1.2 Death one to five years

7

1118

Risk Ratio (M‐H, Random, 95% CI)

1.26 [0.73, 2.17]

1.3 Graft loss including death up to one year

8

1817

Risk Ratio (M‐H, Random, 95% CI)

0.97 [0.64, 1.49]

1.4 Graft loss including death one to five years

7

1092

Risk Ratio (M‐H, Random, 95% CI)

1.41 [1.00, 2.01]

1.5 Graft loss excluding death up to one year

8

1817

Risk Ratio (M‐H, Random, 95% CI)

1.17 [0.72, 1.92]

1.6 Graft loss excluding death one to five years

7

1092

Risk Ratio (M‐H, Random, 95% CI)

1.61 [0.98, 2.64]

2 Rejection Show forest plot

11

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Acute rejection up to one year

10

1913

Risk Ratio (M‐H, Random, 95% CI)

1.77 [1.20, 2.61]

2.2 Biopsy‐proven acute rejection up to one year

5

1292

Risk Ratio (M‐H, Random, 95% CI)

1.32 [0.78, 2.22]

3 New‐onset diabetes after transplantation and cardiovascular events Show forest plot

6

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

3.1 New onset diabetes after transplantation up to five years

6

1439

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.49, 1.21]

3.2 Cardiovascular events up to five years

2

607

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.42, 2.33]

4 Infection and malignancy Show forest plot

7

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

4.1 Infection (all) up to five years

5

1819

Risk Ratio (M‐H, Random, 95% CI)

1.02 [0.84, 1.22]

4.2 CMV infection up to five years

5

1758

Risk Ratio (M‐H, Random, 95% CI)

1.04 [0.80, 1.36]

4.3 Malignancy up to five years

3

756

Risk Ratio (M‐H, Random, 95% CI)

0.77 [0.41, 1.46]

5 Kidney function Show forest plot

8

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

5.1 Serum creatinine (mg/dL) up to one year

4

644

Std. Mean Difference (IV, Random, 95% CI)

‐0.04 [‐0.21, 0.13]

5.2 Serum creatinine (mg/dL) one to five years

5

762

Std. Mean Difference (IV, Random, 95% CI)

0.08 [‐0.06, 0.23]

5.3 Creatinine clearance (mL/min) up to one year

2

215

Std. Mean Difference (IV, Random, 95% CI)

‐0.07 [‐0.35, 0.21]

5.4 Creatinine clearance (mL/min) one to five years

3

669

Std. Mean Difference (IV, Random, 95% CI)

‐0.21 [‐0.56, 0.13]

Figuras y tablas -
Comparison 1. Steroid withdrawal versus steroid maintenance
Comparison 2. Steroid avoidance versus steroid maintenance

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death and graft loss Show forest plot

13

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Death up to one year

10

1462

Risk Ratio (M‐H, Random, 95% CI)

0.96 [0.52, 1.80]

1.2 Death one to five years

7

1201

Risk Ratio (M‐H, Random, 95% CI)

0.57 [0.32, 1.01]

1.3 Graft loss including death up to one year

7

1211

Risk Ratio (M‐H, Random, 95% CI)

1.08 [0.72, 1.62]

1.4 Graft loss including death one to five years

7

1245

Risk Ratio (M‐H, Random, 95% CI)

0.79 [0.53, 1.18]

1.5 Graft loss excluding death up to one year

7

1211

Risk Ratio (M‐H, Random, 95% CI)

1.09 [0.64, 1.86]

1.6 Graft loss excluding death one to five years

7

1245

Risk Ratio (M‐H, Random, 95% CI)

0.98 [0.66, 1.45]

2 Rejection Show forest plot

9

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Acute rejection up to one year

7

835

Risk Ratio (M‐H, Random, 95% CI)

1.58 [1.08, 2.30]

2.2 Biopsy‐proven acute rejection up to one year

6

1073

Risk Ratio (M‐H, Random, 95% CI)

1.94 [1.26, 2.98]

3 New‐onset diabetes after transplantation and cardiovascular events Show forest plot

9

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

3.1 New onset diabetes after transplantation up to five years

9

1618

Risk Ratio (M‐H, Random, 95% CI)

0.75 [0.51, 1.10]

3.2 Cardiovascular events up to five years

4

1013

Risk Ratio (M‐H, Random, 95% CI)

0.56 [0.30, 1.05]

4 Infection and malignancy Show forest plot

11

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

4.1 Infection (all) up to five years

9

1833

Risk Ratio (M‐H, Random, 95% CI)

0.93 [0.84, 1.03]

4.2 CMV Infection up to five years

6

1454

Risk Ratio (M‐H, Random, 95% CI)

0.96 [0.70, 1.31]

4.3 Malignancy up to five years

7

1635

Risk Ratio (M‐H, Random, 95% CI)

0.97 [0.61, 1.52]

5 Kidney function Show forest plot

10

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

5.1 Serum creatinine (mg/dL) up to one year

5

735

Std. Mean Difference (IV, Random, 95% CI)

0.02 [‐0.12, 0.17]

5.2 Serum creatinine (mg/dL) one to five years

3

688

Std. Mean Difference (IV, Random, 95% CI)

‐0.01 [‐0.16, 0.14]

5.3 Creatinine clearance (mL/min) up to one year

6

1104

Std. Mean Difference (IV, Random, 95% CI)

‐0.08 [‐0.23, 0.08]

5.4 Creatinine clearance (mL/min) one to five years

3

563

Std. Mean Difference (IV, Random, 95% CI)

‐0.08 [‐0.25, 0.08]

Figuras y tablas -
Comparison 2. Steroid avoidance versus steroid maintenance
Comparison 3. Steroid avoidance versus steroid withdrawal

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death and graft loss Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Death up to one year

1

222

Risk Ratio (M‐H, Random, 95% CI)

0.39 [0.08, 1.98]

1.2 Death one to five years

2

152

Risk Ratio (M‐H, Random, 95% CI)

2.67 [0.63, 11.32]

1.3 Graft loss including death up to one year

1

222

Risk Ratio (M‐H, Random, 95% CI)

0.86 [0.32, 2.29]

1.4 Graft loss including death one to five years

2

152

Risk Ratio (M‐H, Random, 95% CI)

2.44 [0.89, 6.70]

1.5 Graft loss excluding death up to one year

1

222

Risk Ratio (M‐H, Random, 95% CI)

1.64 [0.40, 6.68]

1.6 Graft loss excluding death one to five years

2

152

Risk Ratio (M‐H, Random, 95% CI)

1.91 [0.48, 7.67]

2 Rejection Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Totals not selected

2.1 Acute rejection up to one year

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

2.2 Biopsy‐proven acute rejection up to one year

1

Risk Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

3 New‐onset diabetes after transplantation, infection, malignancy Show forest plot

3

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

3.1 New onset diabetes after transplantation up to five years

3

351

Risk Ratio (M‐H, Random, 95% CI)

0.63 [0.36, 1.09]

3.2 Infection (all) up to five years

3

374

Risk Ratio (M‐H, Random, 95% CI)

1.07 [0.76, 1.50]

3.3 CMV Infection up to five years

2

284

Risk Ratio (M‐H, Random, 95% CI)

0.53 [0.30, 0.92]

3.4 Malignancy up to five years

1

90

Risk Ratio (M‐H, Random, 95% CI)

1.57 [0.28, 8.94]

4 Kidney function Show forest plot

2

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

4.1 Serum creatinine (mg/dL) up to one year

2

88

Std. Mean Difference (IV, Random, 95% CI)

‐0.05 [‐0.47, 0.37]

4.2 Creatinine clearance (mL/min) up to one year

2

206

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.41, 0.14]

Figuras y tablas -
Comparison 3. Steroid avoidance versus steroid withdrawal
Comparison 4. Steroid withdrawal versus maintenance in children

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Death and graft loss Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

1.1 Death up to five years

2

174

Risk Ratio (M‐H, Random, 95% CI)

0.16 [0.02, 1.35]

1.2 Graft loss including death up to five years

2

174

Risk Ratio (M‐H, Random, 95% CI)

0.09 [0.01, 0.69]

1.3 Graft loss excluding death up to five years

2

174

Risk Ratio (M‐H, Random, 95% CI)

0.09 [0.00, 1.64]

2 Rejection, malignancy Show forest plot

2

Risk Ratio (M‐H, Random, 95% CI)

Subtotals only

2.1 Acute rejection up to one year

2

174

Risk Ratio (M‐H, Random, 95% CI)

0.37 [0.13, 1.02]

2.2 Biopsy‐proven acute rejection up to one year

1

42

Risk Ratio (M‐H, Random, 95% CI)

0.17 [0.01, 3.27]

2.3 Malignancy (PTLD) up to five years

1

132

Risk Ratio (M‐H, Random, 95% CI)

1.89 [0.51, 6.98]

3 Kidney function Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Totals not selected

3.1 Creatinine clearance (mL/min) up to five years

1

Mean Difference (IV, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 4. Steroid withdrawal versus maintenance in children
Comparison 5. Publication bias

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Funnel plots Show forest plot

20

5288

Risk Ratio (M‐H, Fixed, 95% CI)

1.36 [1.15, 1.62]

1.1 Death, steroid withdrawal versus maintenance

10

1913

Risk Ratio (M‐H, Fixed, 95% CI)

0.70 [0.39, 1.29]

1.2 Acute rejection steroid withdrawal versus maintenance

10

1913

Risk Ratio (M‐H, Fixed, 95% CI)

1.55 [1.28, 1.87]

1.3 Death, steroid avoidance versus maintenance

10

1462

Risk Ratio (M‐H, Fixed, 95% CI)

0.92 [0.52, 1.63]

Figuras y tablas -
Comparison 5. Publication bias